lauflumide

Lauflumide (also known as NLS-4, CRL-40,940, or flmodafinil) is a small molecule wake-promoting agent being developed by NLS Pharmaceutics. It is an optically pure R-enantiomer of a bis(p-fluoro)phenyl derivative of modafinil. The drug acts as a selective atypical dopamine reuptake inhibitor (DAT) and also binds to alpha-1A and alpha-1B adrenergic receptors, neuropeptide Y1 (NPY1) receptors (as an inverse agonist), and exhibits histamine H2 receptor activity. Lauflumide is intended for the treatment of various conditions characterized by excessive daytime sleepiness or cognitive impairment, including narcolepsy, idiopathic hypersomnia, attention deficit hyperactivity disorder (ADHD), and chronic fatigue syndrome (including Long-COVID-associated fatigue). Preclinical studies indicate that lauflumide is more potent than modafinil, providing a longer duration of wakefulness without a hypersomnia rebound effect.

Brand names

Quilience

Other names

flmodafinilbisfluoromodafinil2-((bis(4-fluorophenyl)methane)sulfinyl)acetamide